Advertisement

Ovarian Cancer

Immune-Enhancing Nutrition has no Effect on Complication Rates After Radical Cystectomy

Jun 11, 2024

Immune-modulation nutrition did not result in fewer complications in patients undergoing radical cystectomy, results from phase 3 SWOG S1600 trial showed. However, a trend was observed toward fewer pa...

Atezolizumab Added to Chemo and PARP Inhibitor Shows No Benefit in Recurrent Ovarian Cancer

Oct 25, 2023

Atezolizumab plus chemotherapy and maintenance niraparib in late-relapsing recurrent chemotherapy-sensitive ovarian cancer does not significantly improve outcomes. Standard therapy for ovarian ...

OS Benefit With Maintenance Olaparib for Ovarian Cancer

Sep 14, 2022

Addition of maintenance olaparib to bevacizumab provides a clinically meaningful overall survival benefit in patients who are HRD-positive, results from the final analysis of the PAOLA-1 trial show. ...

A prodrug of 3-(ferrocenylaminocarbonyloxymethyl)phenol activated by reactive oxygen species in cancer cells.

May 23, 2022

Hybrid drugs containing ferrocene and phenol residues, whose π systems are not conjugated with each other, exhibit potent anticancer activity as previously reported. Few important open questions are ...

The enhancer RNA ADCY10P1 is associated with the progression of ovarian cancer.

May 16, 2022

Emerging evidence identifies enhancer RNAs (eRNAs) as a class of regulatory ncRNAs that can contribute to the transcription of target genes. In this study, we used an integrated data analysis method t...

LncRNA LINC00665 Promotes Ovarian Cancer Cell Proliferation and Inhibits Apoptosis via Targeting miR-181a-5p/FHDC.

May 09, 2022

Previous reports indicate that long intergenic non-coding RNA LINC00665 naturally occurred vital effects in various cancers. Herein, the role of LINC00665 in ovarian cancer progress was explored. We f...

FBXO2 targets glycosylated SUN2 for ubiquitination and degradation to promote ovarian cancer development.

May 09, 2022

SAD1/UNC84 domain protein-2 (SUN2) plays a tumor suppressor role in various types of cancer by inhibiting cancer cell proliferation, migration and promoting apoptosis. However, the post-translational ...

Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer.

May 02, 2022

Brain metastases from ovarian cancer remain rare and the appropriate treatment is unknown. We investigated survival outcomes following salvage chemotherapy before and after bevacizumab approval to eva...

Differential roles of the Wip1-p38-p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas.

May 02, 2022

Ovarian clear cell carcinoma (OCCC) is one of the most lethal types of ovarian cancer. Early-stage OCCC can be cured by surgery; however, advanced-stage disease shows poor prognosis due to chemoresist...

Patient-Reported Outcomes & Chemotherapy-Related Cognitive Impairment in Gynecologic Malignancy

Apr 29, 2022

Chemotherapy can have a variety of adverse consequences, including chemotherapy-induced cognitive impairment and the term "chemobrain. The research aimed to gain a better understanding of patient-repo...

Outcomes of Open Radical Hysterectomy Following Implementation of An ERAS Program

Apr 29, 2022

Open surgery has become the standard technique for radical hysterectomy (International Federation of Gynecology and Obstetrics (FIGO) 2018 IA1 with lymphovascular space invasion-IIA1). The goal of the...

Microbiome Differs in Black Vs White Women With Gynecologic Cancer

Apr 27, 2022

Black women experience higher mortality from endometrial cancer (EC) than White women, according to published data, and potential reasons for this disparity include increased rates of obesity and more...

Prevalence of Americans reporting a family history of cancer indicative of increased cancer risk: Estimates from the 2015 National Health Interview Survey.

Apr 25, 2022

The collection and evaluation of family health history in a clinical setting presents an opportunity to discuss cancer risk, tailor cancer screening recommendations, and identify people with an increa...

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.

Apr 18, 2022

Although the use of PARP inhibitor has received considerable amount of attention in ovarian cancer, PARP inhibitor resistance still emerges with disease progression. PI3K/AKT pathway inhibitors have b...

Ovarian Cancer Ascites Inhibits Transcriptional Activation of NK Cells Partly through CA125.

Apr 11, 2022

Malignant ascites is a common clinical problem in ovarian cancer. NK cells are present in the ascites, but their antitumor activity is inhibited. The underlying mechanisms of the inhibition have yet t...

Palmitoylation of MDH2 by ZDHHC18 activates mitochondrial respiration and accelerates ovarian cancer growth.

Apr 04, 2022

Epithelial ovarian cancer (EOC) exhibits strong dependency on the tricarboxylic acid (TCA) cycle and oxidative phosphorylation to fuel anabolic process. Here, we show that malate dehydrogenase 2 (MDH2...

Interaction between TMEFF1 and AHNAK proteins in ovarian cancer cells: Implications for clinical prognosis.

Mar 28, 2022

TMEFF1 is a newly discovered protein involved in the physiological functions of the central nervous system, embryonic development, and other biological processes. Our previous study revealed that TMEF...

Tumor-reactive antibodies evolve from non-binding and autoreactive precursors.

Mar 21, 2022

The tumor microenvironment hosts antibody-secreting cells (ASCs) associated with a favorable prognosis in several types of cancer. Patient-derived antibodies have diagnostic and therapeutic potential;...

Plasma-activated medium inhibits cancer stem cell-like properties and exhibits a synergistic effect in combination with cisplatin in ovarian cancer.

Mar 14, 2022

Ovarian cancer stem-like cells (CSCs) have been implicated in tumor recurrence, metastasis, and drug resistance. Accumulating evidence has demonstrated the antitumor effect of plasma-activated medium ...

LncRNA HLA-F-AS1 attenuates the ovarian cancer development by targeting miR-21-3p/PEG3 axis.

Mar 14, 2022

Dysregulated long noncoding RNA (lncRNA) HLA-F-AS1 is depicted in numerous cancers. However, its function in ovarian cancer has yet to be clarified. LncRNA HLA-F-AS1, miR-21-3p, and PEG3 expressions i...

SUBSPECIALTIES

Advertisement